Nefroprotective properties of febuxostat in chronic renal failure
Keywordsterminal renal failure, hyperuricemia, nephroprotective therapy, febuxostat
Urgency. Chronic renal failure poses medical, social and organizational problem because of high mortality, disability and complexity of modern treating methods technical support. The objective: to evaluate the effectiveness of febuxostat in controlling hyperuricemia in patients with end-stage chronic renal failure. Material and methods. 90 patients were divided into three groups in accordance with the use of febuxostat at a dose of 40 mg to reduce uric acid level: group 1 (n=30) - terminal chronic renal failure patients who are not yet receiving renal replacement therapy; Group 2 (n=30) peritoneal dialysis patients; 3 group (n=30)- hemodialysis patients. Results and discussion. Febuxostat use led to uric acid level decrease in all groups under study, increase of the functional renal reserve level in the 1st and 2nd groups. In the 3rd group patients (hemodialysis patients), only uric acid level changes were studied in connection with the absence of in this cohort residual functional renal reserve. The use of febuxostat determines, with decrease in uric acid levels, increase in the residual functional renal reserve and improvement the patients’ quality of life according to the questionnaire data. These results are best reflected in pre-dialysis patients with terminal chronic renal failure. Conclusion: treatment with febuxostat leads to a marked decrease in the level of serum uric acid, increase of residual functional renal reserve and improvement of chronic renal failure patients quality of life, which indicates its good nephroprotective properties.
Petrova M.S., Mazurov V.I., Inamova O.V. Febuxostat for the treatment of chronic hyperuricemia in patients with gout. Medical advice. 2017. No. 17. S. 114-122.
Hyperuricemia and the problem of chronic kidney disease / Shcherbak AV, Kozlovskaya LV, Bobkova IN, et al. Therapeutic archive. 2013. T. 85, No. 6. S. 100-104.
MS Eliseev Chronic kidney disease: role of hyperuricemia and urate-reducing therapy. Modern rheumatology. 2018. Vol.12, No. 1. S. 60-65.
Ivanov DD A New Era of Dialysis: Advanced Hemodialysis (HDx) [Electronic resource]. The kidneys. 2019. Vol.8, No 1. URL: http://www.mif-ua.com/archive/article_print/47142.
Quality of life of patients with chronic kidney disease on renal replacement therapy / Milanovov Yu. S., Dobrosmyslov IA, Milovanova S. Yu., Etc. Therapeutic archive. 2018. No. 6. P.89-91.
Comparative evaluation of the use of allopurinol uricodepressants and febuxostat in gouty nephropathy. Message 1. Clinical trial [Electronic resource] / Ivanov DD, Sinyachenko OV, Bevzenko TB, Fedorov DM Kidneys. 2018. Vol.7, No 3. URL: http://www.mif-ua.com/archive/article/46312.
Efficacy of febuxostat used to slow the decline in glomerular filtration in patients with chronic kidney disease and asymptomatic hyperuricemia / Sircar D., Chatterjee, S. Waikhom, R. et al. International Journal of Endocrinology. 2017. T. 13, No. 1. S. 45-50.
Lien Y. H., Logan J. L. Cross-reactions between allopurinol and febuxostat. Am. J. Med. 2017. Vol. 130, No. 2. R. 67-68.
Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis / Kim S., Kim H. J., Ahn H. S. et al. Kidney Res. Clin. Pract. 2017. Vol. 36, No. 3. R. 274-281.
Singh J. A., Cleveland J. D. Comparative efficacy of allopurinol versus febuxostat for the prevention of incident renal disease in older adults: an analysis of Medicare claims data. Ann. Rheum. Dis. 2017. Vol. 76, No. 10. R. 1669-1678.
How to Cite
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 345
Number of citations: 0